

Inhibitory effects of flavonoids on human immunodeficiency virus type-1 integrase

Supinya TEWTRAKUL,^{a)} Hirotugu MIYASHIRO,^{a)} Masao HATTORI,^{*a)} Tomokazu YOSHINAGA,^{b)}
Tamio FUJIWARA,^{b)} Tsuyoshi TOMIMORI,^{c)} Haruhisa KIZU^{c)} and Yukinori MIYAICHI^{c)}

^{a)}Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan.

^{b)}Shionogi Institute for Medical Science, 2-5-1, Mishima, Settsu-shi, Osaka 566-0022, Japan.

^{c)}School of Pharmacy, Hokuriku University, Ho-3 Kanagawa-machi, Kanazawa, 920-1181, Japan.

(Received September 17, 2001. Accepted November 27, 2001.)

Abstract

One hundred and eighty-three flavonoids were screened for their inhibitory effects on HIV-1 integrase (IN) using a multiplate integration assay (MIA). Of the tested flavonoids, 6-hydroxyluteolin, scutellarein, pedalitin, scutellarin, baicalein dimer, hypolaetin, 7-O-benzyl-6-hydroxyluteolin and baicalein showed appreciable inhibition with IC₅₀ values of 0.4, 0.6, 1.3, 1.7, 2.0, 2.1, 3.0 and 3.6 μ M, respectively. The potent inhibition was observed with flavonoids having at least one pair of vicinal hydroxyl groups and the activity was highly dependent on the number of vicinal hydroxyl groups.

On the other hand, the inhibitory activity tended to be decreased by replacing a hydroxyl group with one of methoxyl, acetoxyl, isopropoxyl, isopentenyl, benzyloxyl, glucuronyl and glycosyl groups. No flavanones, flavanonols and chalcones examined in this experiment showed any significant inhibitory activity.

Key words HIV-1, integrase, inhibitory effect, flavonoid.

Abbreviations HIV-1, human immunodeficiency virus type 1; IN, integrase; RT, reverse transcriptase; PR, protease; LTR, long terminal repeat; DMSO, dimethyl sulfoxide; DNA, deoxyribonucleic acid; MIA, multiplate integration assay; PBS, phosphate-buffered saline; MOPS, 3-(N-morpholino)propane sulfonic acid; DTT, dithiothreitol; AP, alkaline phosphatase; EDTA 2Na, ethylenediaminetetraacetate disodium salt; NP-40, nonidet-P40; IC₅₀, 50% inhibitory concentration; 5-CITEP, 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)propanone.

Introduction

HIV-1 infection remains a world-wide health concern with limited kinds of clinical drugs, in which some compounds have not been recommended for use for a long period of time due to the incidence of viral mutation followed by drug-resistance. Three HIV-1 enzymes are essential to the life cycle of the virus. HIV-1 reverse transcriptase (RT) is crucial for viral replication. HIV-1 protease (PR) processes viral proteins into functional enzymes and structural proteins, thereby facilitating maturation and infectivity of virion particles. HIV-1 integrase (IN) mediates the integration of the double strand DNA

transcript of an HIV-1 RNA genome into the host genome.¹⁾ HIV-1 IN presents an attractive possibility as an antiviral target because host cells do not make or require such enzymes. Recent evidence shows that HIV replication in T-lymphoid cells requires an integrase function.^{2,3)}

Flavonoids are one of the main constituents in plants, and show many biological activities such as antifungal, antibacterial,⁴⁾ anti-inflammatory,⁵⁾ antioxidant,^{6,7)} anticancer⁸⁾ and antiviral activities.⁹⁻¹¹⁾ Effects of flavonoids on RT were investigated by Kusumoto *et al.*¹²⁾ of their tested compounds, 6-hydroxyluteolin, pedalitin, 6-hydroxykaempferol and quercetagenin were the most potent inhibitors with IC₅₀ values of less than 10

*To whom correspondence should be addressed. e-mail : saibo421@ms.toyama-mpu.ac.jp

μM . Flavonoids were also reported to show inhibitory effects on HIV-1 PR.¹³⁾ Recently, a new flavonol galloyl glycoside from *Acer okamotoanum* was reported to exhibit HIV-1 IN inhibitory activity with an IC_{50} value of $18.1 \mu\text{g/ml}$.¹⁴⁾ Since some flavonoids have been shown to have inhibitory action against various enzymes, it is of interest to investigate their inhibitory activity against HIV-1 IN. In the present paper, we report the inhibitory effects of some flavonoids obtained from natural sources, purchased and prepared by chemical synthesis on HIV-1 IN and their structure-activity relationships.

Materials and Methods

Chemicals and enzyme: The sources of flavonoids used in this experiment are described in Tables I and II.¹⁵⁻⁵⁹⁾ All flavonoids were dissolved in 50% DMSO prior to the investigation of HIV-1 IN inhibitory activity.

HIV-1 IN protein was expressed in *Escherichia coli* and the purified enzyme was stored at -80°C before use. Oligonucleotides of long terminal repeat (LTR) donor DNA and substrate DNA were purchased from Japan Bioservice Co. (Asaka, Japan) and stored at -25°C before use. The sequences of biotinylated LTR donor DNA and its unlabelled complement were 5'-biotin-ACCCTTTT-AGTCAGTGTGGAAAATCTCTAGCAGT-3' and 3'-GAAAATCAGTCACACCTTTTATAGAGATCGTCA-5', respectively while those of digoxigenin-labelled target DNA were 5'-TGACCAAGGGCTAATTCAGT-digoxigenin and 3'-digoxigenin-ACTGGTTCCCGATTAAGTGA-5', respectively.

Multiplate integration assay (MIA) procedure:⁶⁰⁾

First, a 96 well plate was coated with $50 \mu\text{l}$ of a streptavidin solution containing $40 \mu\text{g/ml}$ streptavidin, 90 mM Na_2CO_3 and 10 mM KCl. Fifty microliters of a biotinylated LTR donor DNA solution containing 10 mM

Table I. Inhibitory effects of flavonoids on HIV-1 integrase

Compound	Substituents of Flavonoids										IC_{50} (μM)	Source (Ref. No.)
	3	5	6	7	8	2'	3'	4'	5'	6'		
1. Chrysin		OH		OH							>100	15
2.		OH		OGent							>100	16
3. Chrysin 7-O-glucuronide		OH		OGlcUA							>100	16
4.		OPr		OPr							>100	17, 18
5.		OH		OBn							>100	17
6. Apigenin		OH		OH				OH			>100	15
7. Rhoiforin		OH		OGlc ²⁻¹ Rha				OH			>100	19
8.		OH		OPr				OPr			>100	17, 18
9.		OAc		OAc				OAc			>100	17
10.		OH		OMe				OMe			>100	17
11.		OMe		OMe				OMe			>100	17
12. Luteolin		OH		OH			OH	OH			28	20
13.		OH		OH			OPr	OPr			>100	17
14.		OBn		OBn							>100	17
15.		OBn		OBn				OPr			>100	17, 18
16. Cosmosiin acetate		OAc		OGlc-Ac ₄				OAc			>100	21
17. Acacetin		OH		OH				OMe			28	22
18.		OMe		OMe			OMe	OH			>100	Unp.
19. Luteolin tetramethyl-ether		OMe		OMe			OMe	OMe			>100	Unp.
20.		OBn		OBn			OPr	OPr			>100	17
21.		OH		OH			OMe	OH	OMe		>100	23
22.		OMe		OMe			OMe	OMe	OMe		>100	22
23. Baicalein		OH	OH	OH							3.6	24
24. Baicalein-7-O-Glc		OH	OH	OGlc							28	25
25.		OH	OH	OGlc ⁶ -CHO							18	17
26. Oroxin B		OH	OH	OGent							>100	16
27. Baicalin		OH	OH	OGlcUA							5.9	26
28. Baicalein 6-O-Glc		OH	OGlc	OH							22	27
29.		OAc	OAc	OAc							15	17
30. Oroxylin A		OH	OMe	OH							>100	24
31.		OH	OMe	OGlcUA-ME							>100	26
32.		OMe	OMe	OMe							>100	17
33.		OH	OMe	OAc							>100	17
34. Scutellarein		OH	OH	OH				OH			0.63	28
35. Scutellarin		OH	OH	OGlcUA				OH			1.7	28

36.		OH	OH	OPr		OPr		14	17, 18
37. Hispiculin		OH	OMe	OH		OH		>100	16
38. Cirsimaritin		OH	OMe	OMe		OH		>100	29
39. Cirsimarin		OH	OMe	OMe		OGlc		>100	29
40. Embinin		OH	Glc ²	OMe		OMe		>100	30
41. Isovitexin		OH	Glc	OH		OH		>100	31
42. Swertisin		OH	Glc	OMe		OH		>100	32
43.		OAc	Glc-Ac ₄	OMe		OAc		>100	33
44.		OH	Glc	OMe		OMe		>100	32
45. 6-Hydroxyluteolin		OH	OH	OH	OH	OH		0.37	33
46. Eupatorin		OH	OMe	OH	OH	OMe		25	34
47. Pedalitin		OH	OH	OMe	OH	OH		1.3	17
48. Cirsiliol		OH	OMe	OMe	OH	OH		12	17
49. Homuorientin		OH	Glc	OH	OH	OH		12	35
50. Swertiajaponin		OH	Glc	OMe	OH	OH		>100	35
51.		OBn	OBn	OBn	OBn	OBn		>100	17
52.		OH	OMe	OPr	OH	OH		12	17
53.		OH	OH	OBn				>100	17
54.		OH	OH	OGlcUA-BE				17	25
55.		OBn	OBn	OBn				>100	17
56.		OH	OBn	OBn				>100	17
57. Plantaginin		OH	OH	OGlc		OH		4.8	36
58.		OH	OH	OBn		OH		26	17
59.		OBn	OBn	OBn		OBn		>100	17
60.		OH	OH	OBn	OH	OH		3.0	17
61. Hypolaetin		OH		OH	OH	OH		2.1	37
62.		OMe		OH	OMe	OBn	OBn	>100	17
63.		OMe		OBn	OMe	OBn	OBn	>100	17
64. Norwogonin		OH		OH	OH			17	38
65.		OH		OBn	OH			100	17
66.		=O		OBn	=O			>100	17
67. Wogonin		OH		OH	OMe			>100	23
68.		OH		OGlcUA	OMe			>100	22
69.		OH		OMe	OMe			60	38
70.		OH		OBn	OBn			>100	17
71. Isoscutellarein		OH		OH	OH	OH		20	15
72.		OH		OH	OGlcUA	OH		>100	15
73.		OH		OH	OH	OMe		17	17
74.		OH		OH	OMe	OH		>100	25
75.		OH		OMe	OH	OMe		>100	17
76.		OH		OPr	OH	OPr		>100	17
77.		OH		OPr	OMe	OPr		>100	17
78.		OH		OPr	OMe	OH		>100	17
79.		OH		OPr	OMe	OMe		75	17
80. Vitexin		OH		OH	Glc	OH		>100	39
81. Isoswertisin		OH		OMe	Glc	OH		>100	32
82.		OMe		OMe	Glc	OMe		>100	31
83.		OBn		OBn	OBn	OPr		>100	17
84.		OMe		OMe	Me	OMe		>100	17
85.		OH		OH	OMe	OMe		>100	40
86.		OH		OGlcUA	OMe	OMe		>100	41
87. Skullcapflavone I		OH		OMe	OMe	OH		>100	40
88. Scutevulin		OH		OH	OMe	OH	OMe	>100	26
89. Rivularin		OH		OMe	OMe	OH	OMe	>100	41
90.		OMe		OMe	OMe	OMe	OMe	>100	42
91.		OH		OH	OMe	OH	OH	>100	22
92.		OH		OMe	OMe	OGlc		>100	43
93.		OH		OH	OBn	OPr	OPr	>100	17
94.		OH		OBn	OBn	OPr	OPr	40	17
95.		OH		OH	OH	OPr	OPr	4.5	17
96.		OH		OBn	OH	OPr	OPr	>100	17
97.		OH		OBn	OBn	OBn	OBn	50	17
98.		OH		OH	OBn			70	17
99.		OH		OMe	OH			>100	17
100.		OH		OBn	OCH ₂ O(CH ₂) ₂ OMe			>100	Unp.
101.		OH		OH	Bn	OPr		>100	17
102.		OH		OH	OH	OPr		8	17
103.		OH		OBn	OH	OPr		>100	17
104.		OH		OBn	OBn	OPr		>100	17
105.		OH		OMe	OH	OMe		>100	Unp.
106.		OH		OPr	OH	OPr		80	17
107. Skullcapflavone II		OH		OMe	OMe	OH		>100	44

108.		OH	OMe	OH	OMe							>100	45
109.		OH	OMe	OGlcUA	OMe							>100	45
110.		OH	Glc	OH	Ara							>100	46
111.		OH	OMe	OH	OMe	OH						>100	45
112.		OH	OMe	OMe	OMe		OMe	OMe				>100	22
113.		OH	OH	OGlc	2-Pt			OH				26	47
114. Amurensin		OH	OH	OGlc	Pe			OH				15	47
115.		OAc	OAc	OGlc-Ac ₄	Pe			OAc				18	47
116. Panasenoid		OGal ² - Glc	OH	OH				OH				>100	48
117. Kaempferol		OH	OH	OH				OH				40	Com (W)
118. Quercetin		OH	OH	OH			OH	OH				15	Com (W)
119. Quercimeritrin		OH	OH	OGlc			OH	OH				7	49
120. Quercitrin		ORha	OH	OH			OH	OH				>100	Com
121. Hyperin		OGal	OH	OH			OH	OH				>100	(T.K.)
122. Rutin		OGlc ⁶ - Rha	OH	OH			OH	OH				>100	47
123.		OMe	OH	OMe			OMe	OMe				>100	Com (F)
124. Datisctetin		OH	OH	OH		OH			OH			82	Com (F)
125. Myricetin		OH	OH	OH			OH	OH	OH			5.2	50
126. Myricitrin		ORha	OH	OH			OH	OH	OH			6.2	Com (F)
127.		OAc	OAc	OAc			OAc	OAc	OAc			13	Com (F)
128. Anhydroicaritin		OH	OH	OH	Pe			OMe				50	17
129. Nor-icariin		ORha	OH	OGlc	Pe			OH				>100	51
130. Icariin		ORha	OH	OGlc	Pe			OMe				50	52
131.		H, H	OH	OH		OH						>100	52
132. Dihydrobaicalein		H, H	OH	OH								46	41
133.		H, H	OH	OMe	OMe							>100	24
134. DihydrooroxylinA		H, H	OH	OMe	OH							>100	17
135.		H, H	OMe	OMe	OMe							>100	24
136.		H, H	OH	OH	OGlcUA-ME			OH				42	17
137.		H, H	OMe	Me	OMe	OMe	OMe	OMe	OMe	OMe		>100	15
138.		H, H	OH		OH	OMe		OH				>100	53
139.		H, H	OH		OH	OMe	OH					>100	20
140.		H, H	OMe		OH	OMe	OMe					>100	41
141.		H, H	OH		OMe	OMe	OH			OMe		>100	54
142.		H, H	OH		OMe	OMe	OGlcUA-ME			OMe		>100	54
143. Naringin		H, H	OH		OH			OH				>100	41
144. Nephellamuretin		H, OH	OH		OH	Pe		OH				>100	55
145. Phellamurin		H, OH	OH		OGlc	Pe		OH				>100	47
146.		H, OH	OH		OGlc ⁶ -Mem	Pe		OH				100	47
147.		H, OH	OH		OGlc	2-Pt		OH				>100	47
148.			OH	OMe	OMe	OH						>100	47
149.		H, OAc	OAc		OGlc-Ac ₄	Pe		OAc				>100	22
150. Astilbin		H,ORha	OH		OH		OH	OH				>100	47
151.		H, OH	OH		OH		OH			OH		>100	56
152.			OH		OH			OPr				32	51
153. Luteolin 7-O-Glc			OH		OGlc			OH	OH			15	17
154. Luteolin 5-O-Glc			OGlc		OH			OH	OH			40	39
155.			OGlc		OAc			OAc	OAc			11	57
			x Ac ₄										57
156.		OH		OH		OH			OH			>100	58
157.		OH		OGlc-p-Cou				OH				12	59
158. Saponarin		OH	Glc	OGlc				OH				>100	22

*Ara = Arabinose, Glc = Glucose, Gal = Galactose, Gent = Gentiobiose, Rha = Rhamnose, Ac = Acetyl, BE = Butyl-ester, Bn = Benzyl, Me = Methyl, ME = Methyl-ester, GlcUA = Glucuronic acid, Pe = Isopentenyl, Pt = Isopentanol, Pr = Isopropyl, *p*-Cou = para-Coumaroyl, Mem = Methylmalonyl, Unp. = Unpublished, Com (F) = Commercial reagent (Funakoshi), Com (W) = Commercial reagent (Wako), Com (T.K.) = Commercial reagent (Tokyo Kasei). Suramin was used as a positive control and its IC₅₀ value was 2.4 μ M under the same conditions.

Table II. Inhibitory effects of some flavonoids and related compounds on HIV-1 integrase

Compound	IC ₅₀ (μ M)	Source (Ref. No.)
159	2	45
160	>100	17
161	>100	17
162	>100	54
163	>100	54
164	10	37
165	23	37
166	52	19
167	>100	37
168	>100	37
169	>100	37
170	>100	37
171	6.1	37
172	17	Unp.
173	>100	Unp.
174	17	Unp.
175	5.6	37
176	50	19
177	>100	19
178	>100	19
179	>100	19
180	>100	19
181	>100	19
182	>100	19
183	>100	19

Tris-HCl (pH 8.0), 1mM NaCl and 40 fmol/ μ l of LTR donor DNA was added to each well, and the plate was gently shaken at room temperature for 30 min, then washed with phosphate-buffered saline (PBS) pH 7.3, 4 times. A mixture (45 μ l) composed of 12 μ l of IN buffer [containing 150 mM 3-(*N*-morpholino)propane sulfonic acid (MOPS) pH 7.2, 75 mM MnCl₂, 5 mM dithiothreitol (DTT), 25% glycerol and 500 μ g/ml bovine serum albumin], 1 μ l of 5 pmol/ μ l digoxigenin-labelled target DNA and 32 μ l of sterilized water was added into each well. Subsequently, 6 μ l of a sample solution and 9 μ l of 1/10 dilution of HIV-1 IN enzyme were added to the plate and incubated at 37°C for 80 min. The wells were washed with PBS 4 times and then 100 μ l of 500 mU/ml alkaline phosphatase (AP) labelled anti-digoxigenin antibody were added and incubated at 37°C for 1 hr. The plate was washed again with washing buffer containing 0.05% Tween 20 in PBS 4 times and with PBS 4 times. Then, AP buffer (150 μ l) containing 100 mM Tris-HCl (pH 9.5), 100 mM NaCl, 5 mM MgCl₂ and 10 mM *p*-nitrophenyl phosphate was added into each well and incubated at 37°C for 1 hr. Finally, the visible absorbance of each well was determined with a microplate reader (BIO-RAD,

model 3550 UV) at a wavelength of 405 nm. The positive control composed of the reaction mixture, 50% DMSO and HIV-1 IN enzyme, while the negative control was buffer-E containing 20 mM MOPS (pH 7.2), 400 mM potassium glutamate, 1 mM ethylenediaminetetraacetate disodium salt (EDTA 2Na), 0.1% Nonidet-P 40 (NP-40), 20% glycerol, 1 mM DTT and 4 M urea without HIV-1 IN enzyme.

Results and Discussion

The inhibitory effects of 183 flavonoids on HIV-1 IN were examined by an MIA (Fig. 1) as described in




Fig. 1 Schematic illustration of multiplate integration assay procedures for the assay of inhibitory activity of flavonoids against HIV-1 integrase.




Fig. 2 Structures of some flavonoids and related compounds listed in Table II.

Material and Methods. As shown in Tables I and II, 6-hydroxyluteolin (**45**), scutellarein (**34**), pedalitin (**47**), scutellarin (**35**), baicalein dimer (**159**) (see Fig. 2), hypolaetin (**61**), 7-*O*-benzyl-6-hydroxyluteolin (**60**) and baicalein (**23**) showed potent HIV-1 IN inhibitory activity with IC_{50} values of 0.4, 0.6, 1.3, 1.7, 2.0, 2.1, 3.0 and $3.6 \mu M$, respectively. Most of these compounds contain hydroxyl substitutions at adjacent positions 5, 6 and 7 on the A-ring of flavonoids. Of these active compounds, 6-hydroxyluteolin (**45**) showed the most potent HIV-1 IN inhibitory effect. This compound contains two more vicinal hydroxyl groups at C-3' and C-4' on the B-ring. Therefore, it may imply that flavonoids with the higher number of vicinal hydroxyl groups tend to have more potent HIV-1 IN inhibitory activity compared to those with a lower number of them. This was also evident by comparison of anti-HIV-1 IN activity between quercetin (**118**, $IC_{50} = 15 \mu M$) and kaempferol (**117**, $IC_{50} = 40 \mu M$). Introduction of a hydroxyl group at C-3 seems to increase inhibitory activity as shown in the IC_{50} values of quercetin (**118**, $IC_{50} = 15 \mu M$) and luteolin (**12**, $IC_{50} = 28 \mu M$). 6-Hydroxyluteolin (**45**, $IC_{50} = 0.37 \mu M$) having three vicinal hydroxyl substituents at C-5, C-6 and C-7 on the A-ring was more potent inhibitor than myricetin (**125**, $IC_{50} = 5.2 \mu M$) having those at C-3', C-4', and C-5' on the B-ring.

Flavonoids, in which hydroxyl groups are replaced by other groups such as methoxyl, acetoxyl, isopropoxyl, isopentenyl, benzyloxyl, glucuronyl and glucosyl, were found to be lower in the inhibitory activity against HIV-1 IN than those with free hydroxyl groups, except for the case of luteolin 5-*O*-glucoside (**153**) and its hepta-acetate (**154**), where the latter compound showed more potent inhibitory activity (*cf.*, **153**, $IC_{50} = 40 \mu M$ and **154**, $IC_{50} = 11 \mu M$). Of the *O*-glucuronyl and *O*-glucosyl compounds, baicalin (**27**, baicalein 7-*O*-glucuronide, $IC_{50} = 5.9 \mu M$) was more potent than baicalein 7-*O*-glucoside (**24**, $IC_{50} = 28 \mu M$).

Of the 5, 6, 7, 3', 4'-penta-oxygenated flavones, mono- and di-methylation of free hydroxyl groups on the A-ring resulted in appreciable reduction of inhibitory activity as shown in the case of pedalitin (**47**, 6-hydroxyluteolin 7-methyl ether, $IC_{50} = 1.3 \mu M$) and cirsiol (**48**, 6-hydroxyluteolin 6,7-dimethyl ether, $IC_{50} = 12 \mu M$) *vs.* 6-hydroxyluteolin (**45**, $IC_{50} = 0.37 \mu M$). Furthermore, methylation of a hydroxyl group at C-4' on

the B-ring also reduced inhibitory activity as evident from the comparison of the IC_{50} values between eupafolin (**46**, 6-hydroxyluteolin 6,7,4'-trimethyl ether, $IC_{50} = 25 \mu M$) and cirsiol (**48**). Of the luteolin glucosides, luteolin 7-glucoside (**153**, $IC_{50} = 15 \mu M$) was more potent in the inhibition than luteolin 5-glucoside (**154**, $IC_{50} = 40 \mu M$). In most of the flavonoids examined, substitution of a hydroxyl group at C-5 by methoxyl and other groups resulted in abrupt loss of inhibitory activity except for some acetates (**29**, **115** and **127**). These findings also support the possible chelation of a metal cofactor with carbonyl and hydroxyl groups of granulatin⁶¹⁾ or salicylhydrazide at the catalytic site of IN.⁶²⁾

Flavanonols **144-147**, either substituted or unsubstituted at C-3 with a hydroxyl group, showed low inhibitory activity against HIV-1 IN with IC_{50} values of more than $100 \mu M$. Flavanones **131-143** were also inactive except for **132** and **136** with low inhibitory activity ($IC_{50} = 46 \mu M$ and $IC_{50} = 42 \mu M$, respectively), suggesting that the double bond at C-2 and C-3 in the flavonoids may be necessary to the inhibitory effects on HIV-1 IN. Saturation of the double bond leads to loss of planarity in the C-ring, which may prevent the interaction with the active site of IN and/or the intercalation to DNA. Chalcone derivatives **162-163** were also inactive against HIV-1 IN, their IC_{50} values being more than $100 \mu M$. It is implied that the pyrone ring of flavonoids may be associated with potentiation of HIV-1 IN inhibitory activity by fixing two aromatic rings A and B. For flavolignans **164-176**, a hydroxymethyl group on the dioxane ring and adjacent hydroxyl groups at C-3' and C-4' on the B-ring seems to be required for the activity. These criteria could be observed from the inhibitory activity of **171** and **175**, their IC_{50} values being 6.1 and $5.6 \mu M$, respectively.

Various flavonoids have been tested for their inhibitory effects on RT.^{12,63)} The results indicated that the adjacent hydroxyl groups were important for the requirement of HIV-1 RT inhibitory activity, while flavanones, isoflavones and chalcones were inactive. These requirements were similar to those for HIV-1 IN inhibitory activity as shown in the present experiment. However, the structure-activity relationships of flavonoids on HIV-1 IN were somewhat different from those on HIV-1 PR. Baicalein (**23**) and quercetagenin, the potent HIV-1 RT and HIV-1 IN inhibitors were inactive against

HIV-1 PR with IC_{50} values of 480 and 1,000 μM , respectively.¹³⁾ This may imply that the mechanism of action of flavonoids on HIV-1 PR is different from those of HIV-1 RT and HIV-1 IN. On considering the structure of HIV-1 IN, its core domain requires a metal cation as a cofactor which is similar to that of HIV-1 RT. Therefore, it is suggested that the inhibition of flavonoids on HIV-1 RT and HIV-1 IN may be performed by binding or chelating with metal in this domain of these two enzymes HIV-1 IN and HIV-1 RT. In 1991, Kusumoto *et al.*¹²⁾ reported that 6-hydroxyluteolin (**45**) and myricetin (**125**) were non-competitive inhibitors against RT with respect to the substrate and the template-primer. The other consideration about the function of these enzymes is that both of HIV-1 IN and HIV-1 RT are DNA-binding enzymes, while that of HIV-1 PR is protein binding one. Therefore, it may have some hint to show the similarity of structure activity relationships of flavonoids with HIV-1 IN and HIV-1 RT.

Although inhibitory effects of flavonoids on HIV-1 IN were previously reported,⁶⁴⁾ the assay was carried out with radioisotopic and gel-electrophoretic methods for determination of the inhibitory activity, and the number of flavonoids tested was not as many as described in the present study. However, the main conclusions of the structure-activity relationships of flavonoids on the inhibition of HIV-1 IN were similar to those obtained in our experiments; the inhibitory activity was enhanced in proportion to the number of adjacent hydroxyl groups, while the activity was reduced by substitution of a free hydroxyl group with methoxyl or glycosyl groups. It was also reported that stacking with DNA bases at the active site of enzyme could play an important role in the mechanism by which these flavonoids inhibit IN.⁶⁵⁾ Another possible mechanism is that the flavonoids may directly interact at the active site of IN⁶⁶⁾ and then interfere the binding of DNA with IN. For the latter proposed mechanism, the x-ray crystallography and 3-D computerization are now becoming useful techniques for determination of the binding properties between active compounds and IN.

Recently, Goldgur and his co-workers reported the structure of HIV-1 catalytic domain complexed with an inhibitor, 5-CITEP, 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)propanone using computergraphic (molecular docking) and x-ray crystallographic means.⁶⁷⁾

These techniques are useful for determination of binding affinity of each active flavonoid with the active site of IN. In order to know the binding affinity between each active flavonoid and catalytic acidic residues of IN, some details should be further investigated. The IN/inhibitor complex of active flavonoids will usefully provide a platform for the design of new selective HIV-1 IN inhibitors.

Acknowledgment

Part of this study was financially supported by The Japan Health Science Foundation (Tokyo, Japan).

和文抄録

マルチプレートインテグレーション法を用いて183種のフラボノイド類のHIV-1インテグラーゼ阻害効果を検討した。これらのうち6-hydroxyluteolin, scutellarein, pedalitin, scutellarin, baicalein 二量体, hypolaetin, 7-O-benzyl-6-hydroxyluteolin および baicalein は強い阻害を示し、それらの50%阻害濃度はそれぞれ0.4, 0.6, 1.3, 1.7, 2.0, 2.1, 3.0および3.6 μM であった。フラボノイド類による阻害には少なくとも一対の隣接したヒドロキシル基が必要であった。また、隣接したヒドロキシル基の数が増加するに従い、HIV-1インテグラーゼ阻害活性も上昇した。他方、ヒドロキシル基がmethoxyl基, acetoxyl基, isopropoxyl基, isopentenyl基, benzyloxyl基, glucuronyl基及びglycosyl基に置換されると阻害活性は減少あるいは消失した。試験したフラバノン, フラバノール, カルコン類には顕著な阻害活性は認められなかった。

*〒930-0194 富山市杉谷2630

富山医科薬科大学和漢薬研究所 服部征雄

References

- 1) Ng, T. B., Huang, B., Fong, W. P., and Yeung, H.W. : Anti-human immunodeficiency virus (anti-HIV) natural products with special emphasis on HIV reverse transcriptase inhibitors. *Life Sciences* **61**, 943-949, 1997.
- 2) La Femina, R. L., Schneider, C. L., Robbins, H. C., Callahan, P. L., LeGrow, K., Roth, E., Schleif, W. A., and Emimi, E. A.: Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. *J. Virol.* **66**, 7414-7419, 1992.
- 3) Sakai, H., Kawamura, M., Sakuragi, J., Sakuragi, S., Shibata, R., Ishimoto, A., Ono, N., Ueda, S., and Adachi, A. : Integration is

- essential for efficient gene expression of human immunodeficiency virus type 1. *J. Virol.* **67**, 1169-1174, 1993.
- 4) Kujumgiev, H., Tsvetkova, I., Serkedjieva, Y., Bankova, V., Christov, R., and Popov, S. : Antibacterial, antifungal and antiviral activity of propolis. *J. Ethnopharmacol.* **64**, 235-240, 1999.
 - 5) Middleton, E. : Effect of plant flavonoids on immune and inflammatory cell function. *Adv. Experi. Med. Biol.* **439**, 175-182, 1998.
 - 6) Aherne, S. A., and O'Brien, N. M. : Protection by the flavonoids myricetin, quercetin and rutin against hydrogen peroxide-induced DNA damage in Caco-2 and Hep G2 cells. *Nutrition & Cancer* **34**, 160-166, 1999.
 - 7) Terao, J. : Dietary flavonoids as antioxidants *in vivo* : Conjugated metabolites of (-)-epicatechin and quercetin participate in antioxidative defence in blood plasma. *J. Med. Invest.* **46**, 159-168, 1999.
 - 8) Choi, S. U., Ryo, S. Y., Yoon, S. K., Jung, N. P., Park, S. H., Kim, K. H., Choi, E. J., and Lee, C. O. : Effects of flavonoids on the growth and cell cycle of cancer. *Anticancer Res.* **19**, 5229-5233, 1999.
 - 9) Bunyapraphatsara, N., Dechsree, S., Yoosook, C., Herunsalee, A., Panpisutchai, Y. : Antiherpes simplex virus component isolated from *Maclura cochinchinensis*. *Phytomedicine* **6**, 421-424, 2000.
 - 10) Lin, Y. M., Flavin, M. T., Schure, R., Chen, F. C., Sidwell, R., Barnard, D. L., Huffman, J. H., and Kern, E. R. : Antiviral activities of biflavonoids. *Planta Med.* **65**, 120-125, 1998.
 - 11) Vlietinck, A. J., Bruyne, T. D., Apers, S., and Pieters, L. A. : Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. *Planta Med.* **64**, 97-109, 1997.
 - 12) Kusumoto, I. T., Hattori, M., Miyaichi, Y., Tomimori, T., Hanaoka, M., and Namba, T. : Effects of flavonoids and alkaloids on reverse transcriptase. *Shoyakugaku Zasshi* **45**, 240-254, 1991.
 - 13) Brinkworth, R. I., Stoermer, M. J., and Fairlie, D. P. : Flavones are inhibitors of HIV-1 proteinase. *Biochem. Biophys. Res. Comms.* **188**, 631-637, 1992.
 - 14) Kim, H. J., Woo, E. R., Shin, C. G., and Park, H. : A new flavonol glycoside gallate ester from *Acer okamotoanum* and its inhibitory activity against human immunodeficiency virus 1 (HIV-1) integrase. *J. Nat. Prod.* **61**, 145-148, 1998.
 - 15) Miyaichi, Y., Imoto, Y., Saida, H., and Tomimori, T. : Studies on the constituents of *Scutellaria* species. X. On the flavonoid constituents of the leaves of *Scutellaria baicalensis*. *Shoyakugaku Zasshi* **42**, 216-219, 1988.
 - 16) Tomimori, T., Imoto, Y., Ishida, M., Kizu, H., and Namba, T. : Studies on the Nepalese crude drugs. VIII. On the flavonoid constituents of the seed of *Oroxylum indicum*. *Shoyakugaku Zasshi* **42**, 98-101, 1988.
 - 17) Harborne, J. B., Mabry, T. J., and Mabry, H. : "The Flavonoids". Part 1, Chapman & Hall, London, 1975.
 - 18) Inuma, M., Tanaka, T., Iwashima, K., and Matsuura, S. : Synthesis of flavones by the use of isopropyl as a protective group. *Yakugaku Zasshi* **104**, 691-694, 1984.
 - 19) Yasue, M., Itaya, M., Inagaki, M., Kitayama, H., and Kawamura, N. : Studies on the constituents of *Evodiopanax innovans*. I. Isolation of maltol and rhoifolin from the leaves. *Yakugaku Zasshi* **87**, 247-250, 1967.
 - 20) Tomimori, T., Miyaichi, Y., Imoto, Y., and Kizu, H. : Studies on the constituents of *Scutellaria* species. VIII. On the flavonoid constituents of "Ben Zhi Lian", the whole herb of *Scutellaria rivularia*. *Yakugaku Zasshi* **40**, 432-435, 1986.
 - 21) Kikuchi, Y., Miyaichi, Y., Yamaguchi, Y., Kizu, H., and Tomimori, T. : Studies on the Nepalese crude drugs. XII. On the phenolic compounds from the root of *Scutellaria prostrata*. *Chem. Pharm. Bull.* **39**, 1047-1050, 1991.
 - 22) Nikaïdo, T., Ohmoto, T., Sankawa, U., Tomimori, T., Miyaichi, Y., and Imoto, Y. : Inhibition of adenosine 3', 5'-cyclic monophosphate phosphodiesterase by flavonoid. *Chem. Pharm. Bull.* **36**, 654-661, 1988.
 - 23) Fujii, M., Miyaichi, Y., and Tomimori, T. : Flavonoids, phenylethanoid and iridoid constituents of the whole plant of *Pedicularis longiflora* var. *tubiformis*. *Planta Med.* **61**, 584, 1995.
 - 24) Miyaichi, Y., Imoto, Y., Tomimori, T., and Namba, T. : Studies on the Nepalese crude drugs. IX. On the flavonoid constituents of the root of *Scutellaria scandens*. *Chem. Pharm. Bull.* **36**, 2371-2376, 1988.
 - 25) Tomimori, T., Miyaichi, Y., and Imoto, Y. : Studies on the Nepalese crude drugs. IX. On the Nepalese crude drugs. IX. On the flavonoid constituents of the root of *Scutellaria baicalensis*. *Yakugaku Zasshi* **104**, 524-528, 1984.
 - 26) Tomimori, T., Miyaichi, Y. and Kizu, H. : On the flavonoid constituents from the roots of *Scutellaria baicalensis*. *Yakugaku Zasshi* **102**, 388-391, 1982.
 - 27) Mehta, C. R., and Mehta, T. P. : *J. Indian Chem. Soc.* **36**, 46, 1959.
 - 28) Miyaichi, Y., Imoto, Y., Kizu, H., and Tomimori, T. : Studies on the Nepalese crude drugs. X. On the flavonoid and the stilbene constituents of the leaves of *Scutellaria scandens*. *Shoyakugaku Zasshi* **40**, 204-207, 1988.
 - 29) Namba, T., Hattori, M., Takehana, Y., Tsunozuka, M., Tomimori, T., Kizu, H., and Miyaichi, Y. : A flavone from *Artemisia capillaris*. *Phytochemistry* **22**, 1057-1058, 1983.
 - 30) Arisawa, M., Morita, N., Kondo, Y., and Takemoto, T. : Studies on constituents of *Iris* genus plants. VI. The constituents of the rhizome of *Iris florentina* L. and the constituents of the petals of *Iris japonica*. *Yakugaku Zasshi* **93**, 1655-1659, 1973.
 - 31) Komatsu, M., Tomimori, T., Makiguchi, Y., and Asano, K. : Studies on the constituents of *Swertia japonica*. III. On the flavonoid constituents of the plants of *Swertia* spp. *Yakugaku Zasshi* **88**, 832-835, 1968.
 - 32) Komatsu, M., Tomimori, T., and Ito, M. : Studies on the constituents of *Swertia japonica*. I. On the structures of swertisin and isoswertisin. *Chem. Pharm. Bull.* **15**, 263-269, 1967.
 - 33) Morita, N. : Studies on the flavonoid of Sesame leaves. II. Synthesis of demethylpedalitin. *Chem. Pharm. Bull.* **8**, 66-71, 1960.
 - 34) Brieskorn, C. H., and Michel, H. : Flavone from the leaves of *Rosmarinus officinalis*. *Tetrahedron Lett.* **9**, 3447-3448, 1968.
 - 35) Komatsu, M., Tomimori, T., and Makiguchi, Y. : Studies on the constituents of *Swertia japonica*. II. Isolation and structure of new flavonoid, swertiajaponin. *Chem. Pharm. Bull.* **15**, 1567-1572, 1967.
 - 36) Aritomi, M. : Homoplantagin, a new flavonoid glycoside in leaves of *Plantago asiatica*. *Chem. Pharm. Bull.* **15**, 432-435, 1967.
 - 37) Kikuchi, Y., Miyaichi, Y., and Tomimori, T. : Studies on Nepalese crude drugs. XIV. New flavonoids from the root of *Scutellaria prostrata*. *Chem. Pharm. Bull.* **39**, 1466-1472, 1991.
 - 38) Tomimori, T., Miyaichi, Y., Imoto, Y., Kizu, H., and Tanabe, Y. : Studies on the constituents of *Scutellaria* species. II. On the

- flavonoid constituents of the root of *Scutellaria baicalensis*. *Yakugaku Zasshi* **103**, 607-611, 1983.
- 39) Yoshizaki, M., Tomimori, T., and Namba, T. : Pharmacognostic studies on *Gleditsia*. III. Flavonoidal constituents in the leaves of *Gleditsia japonica* and *G. sinensis*. *Chem. Pharm. Bull.* **25**, 3408-3409.
 - 40) Tomimori, T., Miyaichi, Y., Imoto, Y., Kizu, H. : Studies on the constituents of *Scutellaria* species. V. On the flavonoid constituents of "Ban Zhi Lian," the whole herb of *Scutellaria rivularis*. *Shoyakugaku Zasshi* **38**, 249-252, 1984.
 - 41) Miyaichi, Y., Imoto, Y., Tomimori, T. and Lin, C. C. : Studies on the constituents of *Scutellaria* species. IX. On the flavonoid constituents of the root of *Scutellaria indica*. *Chem. Pharm. Bull.* **35**, 3720-3725, 1987.
 - 42) Miyaichi, Y. : Studies on the flavonoid constituents of *Scutellaria* species. Thesis of Toyama Medical and Pharmaceutical University, Toyama, Japan, 1989.
 - 43) Tomimori, T., Imoto, Y., and Miyaichi, Y. : Studies on the constituents of *Scutellaria* species. XIII. On the flavonoid constituents of the root of *Scutellaria rivularis*. *Chem. Pharm. Bull.* **38**, 3488-3490, 1990.
 - 44) Kikuchi, Y., Miyaichi, Y., Yamaguchi, Y., Kizu, H., Tomimori, T., and Vetschera, K. : Studies on the constituents of *Scutellaria* species. XIV. On the constituents of the roots and leaves of *Scutellaria alpina*. *Chem. Pharm. Bull.* **39**, 199-201, 1991.
 - 45) Matsuura, Y., Miyaichi, Y., and Tomimori, T. : Studies on the Nepalese crude drugs. XIX. On the flavonoid and phenylethanoid constituents of the root of *Scutellaria repens*. *Yakugaku Zasshi* **114**, 775-788, 1994.
 - 46) Takagi, S., Yamaki, M., and Inoue, K. : Flavone di-C-glycoside from *Scutellaria baicalensis*. *Phytochemistry* **20**, 2443-2444, 1981.
 - 47) Miyaichi, Y., Segi, H., and Tomimori, T. : Studies on the constituents of the leaves of *Phellodendron japonicum*. *Yakugaku Zasshi* **114**, 186-199, 1994.
 - 48) Komatsu, M., Tomimori, T., and Makiguchi, Y. : Studies on the constituents of the herb of *Panax ginseng*. II. On the flavonoid constituents. *Yakugaku Zasshi* **89**, 122-126, 1969.
 - 49) Kimura, Y., Okuda, H., Tani, T., and Arichi, S. : Studies on *Scutellaria Radix*. VI. Effects of flavanone compounds on lipid peroxidation in rat liver. *Chem. Pharm. Bull.* **30**, 1792-1795, 1982.
 - 50) Tomimori, T., Miyaichi, Y., Imoto, Y., Kizu, H., and Suzuki, C. : Studies on the constituents of *Scutellaria* species. IV. On the flavonoid constituents of the root of *Scutellaria baicalensis*. *Yakugaku Zasshi* **104**, 429-534, 1984.
 - 51) Komatsu, M., Tomimori, T., Hatayama, K., and Mikuriya, N. : Studies on the constituents of *Sophora* species. IV. Constituents of the root of *Sophora angustifolia*. *Yakugaku Zasshi* **99**, 463-468, 1970.
 - 52) Tokuoka, Y., Daigo, K., and Takemoto, T. : Studies on the constituents of *Epimedium*. V. Flavonoids of *Epimedium grandiflorum*. *Yakugaku Zasshi* **95**, 825-829, 1975.
 - 53) Miyaichi, Y., Kizu, H., Tomimori, T., Lin, C. C. : Studies on the constituents of *Scutellaria* species. XI. On the flavonoid constituents of the aerial parts of *Scutellaria indica*. *Chem. Pharm. Bull.* **37**, 794-797, 1989.
 - 54) Tomimori, T., Miyaichi, Y., Imoto, Y., Kizu, H., and Namba, T. : Studies on Nepalese crude drugs. V. On the flavonoid constituents of the root of *Scutellaria discolor*. *Chem. Pharm. Bull.* **33**, 4457-4463, 1985.
 - 55) Miyaichi, Y., Ishii, K., Kuno, T., and Tomimori, T. : Studies on the constituents of *Scutellaria* species. XX. Constituents of roots of *Scutellaria strigillosa*. *Yakugaku Zasshi* **53**, 237-241, 1999.
 - 56) Shimada, H., Sawada, T., and Fukuda, S. : On the constituents of *Astilbe thunbergii*. *Yakugaku Zasshi* **72**, 578-580, 1952.
 - 57) Tomimori, T., Yoshizaki, M., and Namba, T. : Studies on the Nepalese crude drugs. I. On the flavonoid and xanthone constituents of the plants of *Swertia* spp. *Yakugaku Zasshi* **93**, 442-447, 1973.
 - 58) Kubo, M., Kimura, Y., Odani, T., Tani, T., and Namba, T. : Studies on *Scutellaria radix*. Part II. The antibacterial substances. *Planta Med.* **43**, 194-201, 1981.
 - 59) Segawa, A., Miyaichi, Y., and Tomimori, T. : Studies on the constituents of the Nepalese crude drug, "Dronapuspi" (*Leucas cephalotes*). The Pharmaceutical Society of Japan, 117th, abstract, 168, 1997.
 - 60) Tewtrakul, S., Miyashiro, H., Nakamura, N., Hattori, M., Kawahata, T., Otake, T., Yoshinaga, T., Fujiwara, T., Supavita, T., Yuenyongsawad, S., Rattanasuwon, P., and Dej-Adisai, S. : HIV-1 integrase inhibitory substances from *Coleus parvifolius*. *Phytother. Res.* in press, 2002.
 - 61) Pommier, Y., and Neamati, N. : Inhibitors of human immunodeficiency virus integrase. *Adv. Virus. Res.* **52**, 427-458, 1999.
 - 62) Neamati, N., Hong, H., Owen, J. M., Sunder, S., Winslow, H. E., Christensen, J.L., Zhao, H., Burke, T. R., Milne, G.W.A., and Pommier, Y. : Salicylhydrazine-containing inhibitors of HIV-1 integrase : implication for a selective chelation in the integrase active site. *J. Med. Chem.* **41**, 3202-3209, 1999.
 - 63) Ono, K., Nakane, H., Fukushima, M., Chermann, J. C., and Barr'e-Sinoussi, F. : Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerase. *Eur. J. Biochem.* **190**, 469-476, 1990.
 - 64) Fesen, M. R., Pommier, Y., Leteurtre, F., Hiroguchi, S., Yung, J., and Kohn, K. W. : Inhibition of HIV-1 integrase by flavones, caffeic acid phenyl ester (CAPE) and related compounds. *Biochem. Pharm.* **48**, 595-608, 1994.
 - 65) Austin, C. A., Patel, S., Ono, K., Nakane, H., and Fischer, L. M. : Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. *Biochem. J.* **282**, 883-889, 1992.
 - 66) Pommier, Y., Marchand, C., and Neamati, N. : Retroviral integrase inhibitors year 2000. *Antiviral Res.* **47**, 139-148, 2000.
 - 67) Goldgur, Y., Cragie, R., Cohen, G. H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H., and Davies, D. R. : Structure of HIV-1 integrase catalytic domain complexed with an inhibitor : A platform for antiviral drug design. *Proc. Natl. Acad. Sci. USA.* **96**, 13040-13043, 1999.